［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］ MORRIS VK,KENNEDY EB,BAXTER NN,et al.Treatment of metastatic colorectal cancer:ASCO guideline［J］.J Clin Oncol,2023,41(3):678-700.
［3］ BILLER LH,SCHRAG D.Diagnosis and treatment of metastatic colorectal cancer:A review［J］.JAMA,2021,325(7):669-685.
［4］ DE PALMA M,HANAHAN D.Milestones in tumor vascularization and its therapeutic targeting［J］.Nat Cancer,2024,5(6):827-843.
［5］ TELEANU RI,CHIRCOV C,GRUMEZESCU AM,et al.Tumor angiogenesis and anti-angiogenic strategies for cancer treatment［J］.J Clin Med,2019,9(1):84.
［6］ WILHELM SM,DUMAS J,ADNANE L,et al.Regorafenib (BAY 73-4506):a new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity［J］.Int J Cancer,2011,129(1):245-255.
［7］ AKIN TELLI T,BREGNI G,VANHOOREN M,et al.Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer［J］.Cancer Treat Rev,2022,110：102460.
［8］ GROTHEY A,VAN CUTSEM E,SOBRERO A,et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT):an international,multicentre,randomised,placebo-controlled,phase 3 trial［J］.Lancet,2013,381(9863):303-312.
［9］ LI J,QIN S,XU R,et al.Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR):a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2015,16(6):619-629.
［10］ XU J,XU RH,QIN S,et al.Regorafenib in Chinese patients with metastatic colorectal cancer:Subgroup analysis of the phase 3 CONCUR trial［J］.J Gastroenterol Hepatol,2020,35(8):1307-1316.
［11］ VAN CUTSEM E,MARTINELLI E,CASCINU S,et al.Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy:Results of the large,single-arm,open-label phase Ⅲb CONSIGN study［J］.Oncologist,2019,24(2):185-192.
［12］ DUCREUX M,PETERSEN LN,OHLER L,et al.Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective,observational CORRELATE study［J］.Eur J Cancer,2019,123:146-154.
［13］ YEH KH,YANG TS,HSU TC,et al.Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer:CORRELATE Taiwan［J］.J Formos Med Assoc,2021,120(11):2023-2031.
［14］ DANE F,OZGURDAL K,YALCIN S,et al.Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey:the single-arm,open-label REGARD study［J］.BMJ Open,2020,10(3):e027665.
［15］ 刘文博，赵赟博.瑞戈非尼治疗老年晚期结直肠癌患者的有效性和安全性分析［J］.中华老年医学杂志,2021,40(6):761-765.
LIU WB,ZHAO YB.Effectiveness and safety of Regorafenib in elderly patients with metastatic colorectal cancer［J］.Chinese Journal of Geriatrics,2021,40(6):761-765.
［16］ YANG T,XIAO H,LIU X,et al.Vascular normalization:A new window opened for cancer therapies［J］.Front Oncol,2021,11:719836.
［17］ XU D,LIU Y,TANG W,et al.Regorafenib in refractory metastatic colorectal cancer:A multi-center retrospective study［J］.Front Oncol,2022,12:838870.
［18］ MOEHLER M,MICHEL M,STEIN A,et al.A phase Ⅰ dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer［J］.Future Oncol,2021,17(25):3309-3319.
［19］ WANG X,LI Z,SHA D,et al.Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS):A multicenter single-arm phase Ⅱ trial［J］.J Clin Oncol,2023,4(suppl_16):abstr e15567.
［20］ CAO G,WANG X,CHEN H,et al.Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer:a real-world retrospective study［J］.BMC Gastroenterol,2022,22(1):328.
［21］ 彭涛，杨沔，金梁斌,等.肝动脉灌注化疗联合瑞戈非尼治疗结直肠癌肝转移患者的临床研究［J］.中国临床药理学杂志,2024,40(2):185-189.
PENG T,YANG M,JIN LB,et al.Clinical trial of hepatic arterial infusion chemotherapy combined with regorafenib in the treatment of patients with liver metastasis of colorectal cancer［J］.Chinese Journal of Clinical Pharmacology,2024,40(2):185-189.
［22］ CAO F,ZHENG J,LUO J,et al.Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens［J］.J Cancer Res Clin Oncol,2021,147(10):2993-3002.
［23］ LIU YC,CHIANG IT,CHUNG JG,et al.Therapeutic efficacy and inhibitory mechanism of regorafenib combined with radiation in colorectal cancer［J］.In Vivo,2020,34(6):3217-3224.
［24］ WALTER T,HAWKINS NS,POLLOCK RF,et al.Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer［J］.J Cancer Res Clin Oncol,2020,146(10):2575-2587.
［25］ BENSON AB,VENOOK AP,AL-HAWARY MM,et al.Colon cancer,version 2.2021,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2021,19(3):329-359.
［26］ GROSSER OS,RUF J,KUPITZ D,et al.Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-microspheres used in preradioembolization dosimetry:Influence on the liver-lung shunt［J］.J Nucl Med,2016,57(6):925-927.
［27］ KENNEDY A,SHIPLEY D,SHPAK M,et al.Regorafenib prior to selective internal radiation therapy using (90)Y-Resin microspheres for refractory metastatic colorectal cancer liver metastases:Analysis of safety,dosimetry,and molecular markers［J］.Front Oncol,2019,9:624.
［28］ ZHOU S,WANG C,SHEN L,et al.Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer:protocol for a prospective,randomized,controlled phase Ⅱ clinical trial (SLOT)［J］.Front Oncol,2023,13:1274487.
［29］ PICARD E,VERSCHOOR CP,MA GW,et al.Relationships between immune landscapes,genetic subtypes and responses to immunotherapy in colorectal cancer［J］.Front Immunol,2020,11:369.
［30］ GROTHEY ATJ,ARNOLD D,DE GRAMONT A,et al.Fluoropyrimidine (FP)+bevacizumab (BEV)+atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC):Findings from Cohort 2 of MODUL-a multicenter randomized trial of biomarker-driven maintenance treatment following first-line induction therapy［J］.Ann Oncol,2018,29(suppl_8):abstract LBA19.
［31］ METTU NB,TWOHY E,OU FS，et al.533PD-BACCI:A phase Ⅱ randomized,double-blind,multicenter,placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC):An ACCRU network study［J］.Ann Oncol,2019,30(5):v198-v252.
［32］ FUKUOKA S,HARA H,TAKAHASHI N,et al.Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer:An open-label,dose-escalation,and dose-expansion phase Ⅰb trial (REGONIVO,EPOC1603)［J］.J Clin Oncol,2020,38(18):2053-2061.
［33］ WANG F,HE MM,YAO YC,et al.Regorafenib plus toripalimab in patients with metastatic colorectal cancer:a phase Ⅰb/Ⅱ clinical trial and gut microbiome analysis［J］.Cell Rep Med,2021,2(9):100383.
［34］ WANG C,CHEVALIER D,SALUJA J,et al.Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer［J］.Oncologist,2020,25(8):e1188-e1194.
［35］ FAKIH M,SANDHU J,LIM D,et al.Regorafenib,ipilimumab,and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy:A phase 1 nonrandomized clinical trial［J］.JAMA Oncol,2023,9(5):627-634.
［36］ QU W,LIU Z,CHEN X,et al.Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer:a multicenter,real-world retrospective study in China［J］.BMC Cancer,2024,24(1):22.
［37］ WANG F,JIN Y,WANG M,et al.Combined anti-PD-1,HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer:a randomized phase 2 trial［J］.Nat Med,2024,30(4):1035-1043.
［38］ LIU YC,TSAI JJ,WENG YS,et al.Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer［J］.Biomed Pharmacother,2020,128:110319.
［39］ SHITARA K,YAMANAKA T,DENDA T,et al.REVERCE:a randomized phase Ⅱ study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients［J］.Ann Oncol,2019,30(2):259-265.
［40］ BEKAII-SAAB TS,OU FS,AHN DH,et al.Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS):a randomised,multicentre,open-label,phase 2 study［J］.Lancet Oncol,2019,20(8):1070-1082.
［41］ SCHULZ H,JANSSEN J,STRAUSS UP,et al.Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany:Final results of the prospective multicentre non-interventional RECORA study［J］.J Clin Oncol,2018,36(suppl_4S):abstract 748.
［42］ CONDE E,EARL J,CRESPO-TORO L,et al.Biomarkers associated with regorafenib first-line treatment benefits in metastatic colorectal cancer patients:REFRAME molecular study［J］.Cancers (Basel),2021,13(7):1710.
［43］ UNSELD M,BELIC J,PIERER K,et al.A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients.Results from the regorafenib's liquid biopsy translational biomarker phase Ⅱ pilot study［J］.Int J Cancer,2021,148(6):1452-1461.
［44］ HSU HC,HUANG KC,CHEN WS,et al.Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden,slow growth and poor/scanty spread［J］.Sci Rep,2021,11(1):15370.
［45］ DAI X,DING W,HE Y,et al.Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy:a real-world study［J］.Front Oncol,2023,13:1227644.
［46］ KOBAYASHI K,KAWAKAMI K,YOKOKAWA T,et al.Association of hand-foot skin reaction with regorafenib efficacy in the treatment of metastatic colorectal cancer［J］.Oncology,2019,96(4):200-206.